| Q36214669 | A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? |
| Q34237240 | A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction |
| Q33542536 | Comparative tolerability and efficacy of treatments for impotence |
| Q34552997 | Cyclodextrin-based pharmaceutics: past, present and future |
| Q24673071 | Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist |
| Q34679612 | Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease |
| Q34707317 | Intracavernosal therapy: when oral agents fail |
| Q53918289 | Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. |
| Q44619794 | Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis |
| Q44803726 | Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy |
| Q34707675 | Oral and injectable medications for the treatment of erectile dysfunction |
| Q24247137 | Prostaglandin E1 for treatment of erectile dysfunction |
| Q87333423 | [Conservative therapy of erectile dysfunction] |